You are here » Home » Companies » Company Overview » Zyden Gentec Ltd

Zyden Gentec Ltd.

BSE: 530091 Sector: Health care
NSE: N.A. ISIN Code: INE622B01045
BSE 00:00 | 04 Mar Zyden Gentec Ltd
NSE 05:30 | 01 Jan Zyden Gentec Ltd
OPEN 1.19
PREVIOUS CLOSE 1.23
VOLUME 69444
52-Week high 1.24
52-Week low 0.00
P/E 12.30
Mkt Cap.(Rs cr) 7
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1.19
CLOSE 1.23
VOLUME 69444
52-Week high 1.24
52-Week low 0.00
P/E 12.30
Mkt Cap.(Rs cr) 7
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Zyden Gentec Ltd. (ZYDENGENTEC) - Chairman Speech

Company chairman speech

ZYDEN GENTEC LIMITED ANNUAL REPORT 2005-2006 CHAIRMAN'S REPORT CHAIRMAN'S STATEMENT Dear Members, It is my privilege to provide the leadership to your company for more than a decade. The vision of positioning the company as one of the valuable corporations of India has been the inspirational force throughout, while handling the reins of the company. We have successfully transformed the difficult strategic choice of creating drivers of growth by matching proven internal capabilities with emerging market opportunities. It is a matter of pride and deep satisfaction for the team that during this period we have not only grown the company to a significant size, but also created enormous shareholder value. As we progress into 2006, we see a world of new opportunities. The global pharmaceutical industry is undergoing dynamic changes in the business environment. On one hand, the developed markets led by the US are being subjected to severe price erosion, while on other hand, emerging markets have witnessed further increase in generic penetration, providing newer opportunities to companies such as ours. The industry experienced consolidation amongst its players, a trend that is expected to gain momentum in the future. While our journey to become a discovery-led pharmaceutical player continues unabated, we also have performed well during the year. As a part of consolidation process and as the company keeps growing, various options are being explored on acquisitions. The company has also been in process of furthering business tie-ups with various players of repute. The performance of the company during 2005-06 was in line with the business plans and the long term objectives. Aim Zyden offers its core competence in the field of new drug lead discovery. Amino acid sequencing to understand receptor drug interactions and creating logical ideas to modify Drug disease inter-relationship by modifying & extending the HLB concept in diseases like Cerebral Malaria, Arthritis, AIDS & Cancer. Planning Strategies Retrosynthesis and Creativity. Complex Organic Molecules and ingenious synthetic solutions both in the field of Regio and Stereo synthesis. This can be well assessed in the synthesis of Estrone or a multi-step synthesis of Camptothecin Nucleus in Analog. Manipulations of are centered around the creation of an Alkaloidal Skeleton with both Hydrophilic as well as Lipohilic centres. Operational Area Application and Applied Research in the field of Anti-Diabetic Type II Drugs and potential leads in Psoriasis. This work also includes Analytical Profiling, Bio-transformation and deduction of potential impurities in molecules which have pharmacologically interesting activities. Pipeline of Actives Since every chemical has a potential usage, a rapid methodology of synthesis has been undertaken to synthesize compounds which have applications. Lot of thinking goes in creating Analogs and series where attempts are made to create long or short Carbon Chains, replace Amides with Thioamides, protect Ketone to create Ketals and introduce carrier groups. Zyden offers the inter-phase to provide better solutions to older cumbersome chemistry. This inter-phase also gives chance to biologists to use immense number of diverse compounds for their profiling, resulting in faster solutions. Successful growth will create risks and the risk management brings with it optimism. However, there are many challenges ahead. There is a challenge of successful integration; of being a global company; of creating managerial pool; of dealing with increasing competitive pressures; of systematically making successful launches across the entire product space; of further strengthening the R&D; and of maintaining the momentum of rapid transformation to become a globally recognized, discovery- led pharmaceutical player. With the various initiatives underway and the new product launches planned for 2006-07, the company would be able to record an even better and improved performance in 2006-07, capitalizing on the over-all, newly emerging off-patent opportunities. I sincerely thank all for continuing to repose confidence in the company as well as in the operating management. Collectively, we will certainly maintain your trust and confidence. Yours sincerely, Sd/- Date : 25th August, 2006 Vinod S Gupta Place : Kota Chairman
.